Anaptysbio (ANAB) Total Liabilities (2016 - 2026)

Anaptysbio has reported Total Liabilities for 11 years, with the latest figure at $316.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 18.32% year-over-year to $316.9 million; the trailing twelve-month figure through Mar 2026 stood at $316.9 million (down 18.32% YoY), and the FY2025 full-year result was $327.2 million, down 20.77% from the prior year.
• Total Liabilities for Q1 2026 stood at $316.9 million, down from $327.2 million in the prior quarter.
• The five-year high for Total Liabilities was $417.5 million in Q2 2024, with the low at $294.4 million in Q1 2022.
• Historically, Total Liabilities has averaged $360.9 million across 5 years, with a median of $364.3 million in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities soared 1934.02% — and 2025, when it slipped 20.77%.
• Anaptysbio's Total Liabilities stood at $348.3 million in 2022, then climbed by 4.6% to $364.3 million in 2023, then rose by 13.36% to $413.0 million in 2024, then declined by 20.77% to $327.2 million in 2025, then dropped by 3.13% to $316.9 million in 2026.
• The last three Total Liabilities figures came in at $316.9 million (Q1 2026), $327.2 million (Q4 2025), and $382.5 million (Q3 2025), per Business Quant data.